venous thrombosis

Displaying 15 studies

  • A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Scottsdale/Phoenix, AZ

    The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.

  • A Study to Collect Information about Biomarkers (Lab Test Results) that May Help to Predict Which People with Calf Vein Clots May be at Higher or Lower Risk of Having the Clot Grow or Progress Rochester, MN

    This is a biomarker correlate study for a study which is randomizing patients with calf deep venous thrombosis (calf vein clots) to treatment with blood thinners or not to see if the blood thinner is necessary. 

  • Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL

    This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous ...

  • The Relationship Between Deep Venous Thrombus Characteristics and Venous Dynamics with Subsequent Thrombus Resolution and Post-thrombotic Syndrome Rochester, MN

    The purpose of this study is to complete the following aims:

    Aim 1: Evaluate initial thrombus characteristics by ultrasound (US) shear wave elastography (SWE) in acute, proximal, deep venous thrombus (DVT).

    Aim 2: Prospectively evaluate the role of venous hemodynamics on acute proximal DVT resolution and post-thrombotic syndrome (PTS).

    Aim 3: Examine biomarkers of coagulation as predictors of acute proximal DVT resolution and PTS.

    Aim 4: Expand the scope of the Mayo Clinic VTE registry to include high quality outcome data on post-thrombotic syndrome.

  • A Study to Identify Genes Responsible for Venous Thromboembolism (VTE) in Families Rochester, MN

    The purpose of this study is to identify susceptibility genes for venous thromboembolism (VTE) using conventional and novel genetic-epidemiologic methods in high-risk VTE families.

  • Intermittent Pneumatic Compression Device Assessment in Patients with Severe Arterial and Venous Disease of the Lower Extremity Rochester, MN

    The purpose of this study is to determine whether a specific external compression pump called the AVT pump can improve blood flow to the skin of the feet in patients with circulatory problems involving the arteries or veins of the legs. The use of the AVT pump in this study is considered investigational, which means it has either not been approved by the Food and Drug Administration (FDA) for routine clinical use or for the use described in this study.

  • Multi-Center Prospective Validation Study of VTE Risk Prediction Tool in Trauma Patients Rochester, MN

    Almost one-half million people suffer venous thromboembolism annually in the United States, and one-third die from this disease. Massive bleeding from injury accounts for half of early deaths after trauma. This study aims to prevent the deaths and suffering associated with venous thromboembolism and bleeding by identifying the individual person at high risk of these complications in order to take preventive measures.

  • Registry of Patients Prescribed Anticoagulation Rochester, MN

    The Gonda Vascular Center- Thrombophilia Clinic at Mayo Clinic in Rochester, Minnesota utilizes a standardized, guideline-directed, yet patient-oriented approach for treating patients diagnosed with venous thrombo embolism (VTE). The rates of VTE recurrence, major bleeding, clinically relevant non-major bleeding (CRNMB) and survival in patients treated with anticoagulation for acute VTE are assessed during prospective observation. VTE cases include an acute deep vein thrombosis (DVT) of lower or upper extremities, splanchnic veins, gonadal, renal, cerebral veins thrombosis and pulmonary embolism (PE). Therapy includes the whole spectrum of FDA approved anticoagulants such as "classic" agents: warfarin and heparinoids and the newer direct ...

  • A Study of Pharmacogenomics Testing in Patients Who Experience Bleeding While on Apixaban or Warfarin Scottsdale/Phoenix, AZ; Rochester, MN

    The purpose of htis study is to see if PGx testing will help to determine better ways for doctors to use apixaban treatment.

  • Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE) Rochester, MN

    The Researchers are studying whether a vascular boot warming program plus standard of care anticoagulation can be a safe and effective method to resolve Deep Vein Thrombosis (DVT) ±Pulmonary Embolism (PE) earlier and prevent development of post-thrombotic syndrome (PTS). Additionally, to learn whether a more detailed imaging of the affected lower extremities will provide a more accurate and reliable method to guide treatment for this condition.

  • Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN; Eau Claire, WI

    This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related blood clots in cancer patients who have completed anticoagulation therapy. Apixaban may stop the clotting of blood by blocking some of the enzymes needed for blood clotting.

  • IPSS Consortium Study Rochester, MN

    The overall objective of our network of investigators is to develop and conduct clinical trials and other large multi-centre studies in childhood stroke. Our specific aims are:

    Objective 1: To ascertain in a prospective, consecutive cohort study the numbers of newborns and children with ischemic stroke, their stroke sub-types and risk factors, their current treatments and outcomes within our centers. These data will provide the rationale and feasibility data for our group to design and implement the initial randomized controlled trials (RCTs) in paediatric stroke as well as other fundable grant proposals.

    Objective 2: To develop standardized data collection forms and an ...

  • A Study to Create and Maintain Plasma and Serum Bank for Patients with Thrombosis Rochester, MN

    The purpose of this study is to create and maintain a clinical database of patients with history of, or who are at high risk for thromboembolic diseases, along with a plasma/serum repository. We plan to evaluate novel biomarkers that might be associated with thromboembolic diseases and test whether these biomarkers will help predict the incident and recurrentrecurrences of thromboembolic episodes and other outcomes (e.g., mortality, post thrombotic syndrome).

  • A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase Rochester, MN

    The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling).

  • A Study to Evaluate the Effectiveness and Safety of Rivaroxaban as Prophylaxis Treatment for Venous Thromboembolism (VTE) in Ambulatory Cancer Patients Rochester, MN

    The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult patients with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.


Mayo Clinic Footer